Showing results (191-200 of 218) with videos related to
Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trialCédric Panje, Stefanie Hayoz, Wolfgang Eisterer, et al.European Journal of Cancer (Oxford, England : 1990)|March 21, 2024
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendationsDaniel L Hertz, Markus Joerger, Yung-Jue Bang, et al.Journal of Cancer Research and Clinical Oncology|October 14, 2004
Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancerMichael Stahl, Hansjochen Wilke, Martin Stuschke, et al.Radiation Oncology (London, England)|May 22, 2015
Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and SwitzerlandPaul Martin Putora, Laurent Bedenne, Wilfried Budach, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagusMichael Stahl, Martin Stuschke, Nils Lehmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2009
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junctionMichael Stahl, Martin K Walz, Martin Stuschke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working GroupRalf-Dieter Hofheinz, Deniz Gencer, Holger Schulz, et al.British Journal of Cancer|November 25, 2020
Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUPGunnar Folprecht, Karolin Trautmann, Alexander Stein, et al.British Journal of Cancer|July 11, 2018
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancerMaren Knödler, Justus Körfer, Volker Kunzmann, et al.European Journal of Cancer (Oxford, England : 1990)|February 24, 2022
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIOSylvie Lorenzen, Peter Thuss-Patience, Claudia Pauligk, et al.Pageof 22